aav2 2 vector Search Results


aav2 2 cag flex archt tdtomato  (Addgene inc)
93
Addgene inc aav2 2 cag flex archt tdtomato
Aav2 2 Cag Flex Archt Tdtomato, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2 2 cag flex archt tdtomato/product/Addgene inc
Average 93 stars, based on 1 article reviews
aav2 2 cag flex archt tdtomato - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
custom aav2/2 and aav2/8 gene therapy vectors (referred to as aav2 and aav8 in this report)  (Vector Biolabs)
90
Vector Biolabs custom aav2/2 and aav2/8 gene therapy vectors (referred to as aav2 and aav8 in this report)
(A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with <t>AAV2</t> or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)
Custom Aav2/2 And Aav2/8 Gene Therapy Vectors (Referred To As Aav2 And Aav8 In This Report), supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/custom aav2/2 and aav2/8 gene therapy vectors (referred to as aav2 and aav8 in this report)/product/Vector Biolabs
Average 90 stars, based on 1 article reviews
custom aav2/2 and aav2/8 gene therapy vectors (referred to as aav2 and aav8 in this report) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
aav2 2 vector  (Addgene inc)
94
Addgene inc aav2 2 vector
(A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with <t>AAV2</t> or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)
Aav2 2 Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2 2 vector/product/Addgene inc
Average 94 stars, based on 1 article reviews
aav2 2 vector - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
virus strains  (Addgene inc)
96
Addgene inc virus strains
(A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with <t>AAV2</t> or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)
Virus Strains, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/virus strains/product/Addgene inc
Average 96 stars, based on 1 article reviews
virus strains - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
aav2/2 serotype  (Virovek Inc)
90
Virovek Inc aav2/2 serotype
(A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with <t>AAV2</t> or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)
Aav2/2 Serotype, supplied by Virovek Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2/2 serotype/product/Virovek Inc
Average 90 stars, based on 1 article reviews
aav2/2 serotype - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
aav2 2 cag flex tdtomato  (Addgene inc)
96
Addgene inc aav2 2 cag flex tdtomato
(A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with <t>AAV2</t> or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)
Aav2 2 Cag Flex Tdtomato, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2 2 cag flex tdtomato/product/Addgene inc
Average 96 stars, based on 1 article reviews
aav2 2 cag flex tdtomato - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
aav2.2 murine nmnat1  (Vector Biolabs)
90
Vector Biolabs aav2.2 murine nmnat1
(A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with <t>AAV2</t> or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)
Aav2.2 Murine Nmnat1, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2.2 murine nmnat1/product/Vector Biolabs
Average 90 stars, based on 1 article reviews
aav2.2 murine nmnat1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
aav2/2  (Addgene inc)
90
Addgene inc aav2/2
(A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with <t>AAV2</t> or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)
Aav2/2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2/2/product/Addgene inc
Average 90 stars, based on 1 article reviews
aav2/2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
chicken polyclonal anti-gfp  (Thermo Fisher)
90
Thermo Fisher chicken polyclonal anti-gfp
(A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with <t>AAV2</t> or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)
Chicken Polyclonal Anti Gfp, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chicken polyclonal anti-gfp/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
chicken polyclonal anti-gfp - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


(A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with AAV2 or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)

Journal: Journal of Cellular and Molecular Medicine

Article Title: Gene replacement therapy restores RCBTB1 expression and cilium length in patient‐derived retinal pigment epithelium

doi: 10.1111/jcmm.16911

Figure Lengend Snippet: (A) Micrographs show morphology and pigmentation of mature patient‐derived RPE monolayers, six months after plating. No changes in RPE morphology were evident two weeks after treatment with AAV2 or AAV8 vectors. (B) RCBTB1 expression was measured in patient‐derived RPE by qRT‐PCR, two weeks after treatment. Data were normalized to GAPDH expression and expressed as mean fold change compared with untreated controls (* p < 0.05). (C) Gene expression was measured by qRT‐PCR in AAV‐RCBTB1–treated and untreated patient‐derived RPE monolayers, 2 weeks after transduction. Bars indicate mean expression values normalized to control levels. Error bars show standard deviation. Statistical significance was determined by the t test (* p < 0.05 and ** p < 0.01). (D) Mean cilium lengths in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE cells, compared with untreated controls. Error bars indicate standard error of the mean. Statistical significance was determined by the t test (** p < 0.01 and *** p < 0.001) (E) RPE cells were cultured, fixed and immunostained for ARL13B and pericentrin, two weeks after treatment with AAV2‐ or AAV8‐RCBTB1 gene therapy vectors. Primary cilium length distributions in AAV2‐RCBTB1– and AAV8‐RCBTB1–treated RPE are compared with untreated patient RPE (chi‐squared test, p < 0.0001)

Article Snippet: Custom AAV2/2 and AAV2/8 gene therapy vectors (referred to as AAV2 and AAV8 in this report) were manufactured by Vector Biolabs.

Techniques: Derivative Assay, Expressing, Quantitative RT-PCR, Transduction, Standard Deviation, Cell Culture